search

Erythropoiesis-stimulating agent should be considered in below set of patients

Erythropoiesis-stimulating agent should be considered in below set of patients:1

Change for Better...Change to

Abbreviations ▼

CKD: Chronic kidney disease; CVD: Cardiovascular disease; Hb: Hemoglobin; HRQoL: Health-related quality of life; KDIGO: Kidney Disease Improving Global Outcomes.

References ▼

LMRC Code: GGI-CO-A1-AQS-DCVN-BANNERS-I23-0349

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cresp

 Cresp®(Biosimilar of darbepoetin alpha), a product by Dr. Reddy's is an erythropoiesis-stimulating agent which helps in treatment of renal anemia in pre-dialysis patients

Cresp

Related Articles

Priority: Impact of rHuEPO on CKD Anemia Care

Priority: Impact of rHuEPO on CKD Anemia Care

Darbepoetin Alfa: Convenient Solution For Managing Anemia!

Cresp the world's firts biosimilar darbepoetin alfa,others improved, conveient, and affordable treatment for anemia

Exploring Darbepoetin Alfa Potential Versus Epoetin Beta

Exploring Darbepoetin Alfa Potential Versus Epoetin Beta

Cresp®, the world's first biosimilar darbepoetin alfa, offers improved, convenient, and affordable treatment for anemia

Compassion in Healthcare

ICML Revisited 2

Factors that affect the response to vadadustat in those with anemia associated with chronic kidney disease

The effect of ziltivekimab on hemoglobin levels in individuals with CKD stage 3-5

Continuous PEGasparaginase dosing regimen decreases hypersensitivity reactions in children with acute lymphoblastic leukemia

The impact of C-reactive protein on the efficacy of roxadustat in managing anemia in chronic kidney disease

Impact of high-dose intravenous iron on treatment outcomes and cardiovascular events in hemodialysis patients with renal anemia